BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 23, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2003

View Archived Issues

Four series of antiangiogenic peptides described by Abbott scientists

Read More

Merck claims novel tyrosine kinase inhibitors for use in cancer and other disorders

Read More

New PTP inhibitors prepared and tested at Applied Research Systems

Read More

Neurotrophic and neuroprotective agents identified by Toyama researchers

Read More

New HCV NS5B polymerase inhibitors in GSK development pipeline

Read More

Inhibitors of IKK2 and potential uses described in recent patent

Read More

New adenosine antagonists with utility in constipation, IBS, etc., covered by Eisai patent

Read More

Selenium reduces the risk of progression toward cancer in patients with Barrett's esophagus

Read More

Initial phase III results for canker sore treatment OraDisc A

Read More

Generex schedules Canadian phase IIb trials of Oralin

Read More

Cellegy appoints Neopharm to distribute Tostrex in Israel

Read More

Femara increases survival in advanced breast cancer

Read More

Fuzeon approved in E.U.

Read More

NM-702 enters late phase II trial for chronic arterial occlusion

Read More

DB-289 enters phase IIb PCP trial

Read More

Results for Thalomid and IMiDs in all stages of multiple myeloma

Read More

Arimidex evaluated in women at high risk for breast cancer, very early breast cancer

Read More

IND filed for Corus-1020, first patient enrolled in cystic fibrosis study

Read More

Orphan drug status awarded to KSB-303 for pancreatic cancer

Read More

Medarex reports preclinical results for anthrax antibody

Read More

Lilly terminates licensing agreement with Ono

Read More

PT-100 shows promise in chemotherapy-induced neutropenia

Read More

IND cleared for VaxGen's anthrax vaccine

Read More

Protherics intends to acquire Enact

Read More

Preliminary evaluation of novel 5-HT2B antagonist indicates potential in IBS

Read More

Prous Science announces the publication of a comprehensive review on SARS

Read More

Selective eradication of H. pylori with BYK-170424

Read More

Inotek advances orally active PARP inhibitor through clinical trials

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 22, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing